Coming to Terms with the FDA Commissioner
This article was originally published in RPM Report
Executive Summary
The Institute of Medicine thinks FDA needs more stability at the highest level, and thinks a six-year fixed term for the commissioner is a good solution. But FDA's new commissioner doesn't agree.
You may also be interested in...
Building the Right Foundation: An Interview with Mark McClellan
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
What's Old Is New: Former Commissioners and the Future of FDA
Four ex-commissioners outline their ideas for reforming the Food & Drug Administration. They don't think new ideas are necessary: just follow through on their old favorites.
What's Old Is New: Former Commissioners and the Future of FDA
Four ex-commissioners outline their ideas for reforming the Food & Drug Administration. They don't think new ideas are necessary: just follow through on their old favorites.